Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Universitas Indonesia Faculty of Medicine (FMUI) and the University of Oxford's Eijkman Oxford Clinical Research Unit (EOCRU, embedded with the Eijkman Institute of Molecular Biology, EIMB, and part of the Vietnam/Asia Wellcome research programme) have completed a facility dedicated to the support of the many collaborative clinical research activities between the two universities.

EOCRU IOCRL (Universities of Indonesia and Oxford Clinical Research Laboratory) team, with Kevin Baird and Guy Thwaites

Hosted by the Department of Parasitology on the FMUI campus in central Jakarta, the Universities of Indonesia and Oxford Clinical Research Laboratory (IOCRL) provides an integrated medium for broader engagement with all of our Indonesian friends and partners in training, education, public engagement, and development of a broader collaborative clinical research agenda in the coming years. The IOCRL facility will be managing three active clinical trials in the coming year:

  • ACT-HIV, assessment of adjunctive dexamethasone therapy for TB meningitis in HIV-infected patients at Cipto Mangungkusomo and Persehabatan Hospitals in Jakarta (Wellcome);
  • INSPECTOR pivotal clinical trial of tafenoquine combined with an artemisinin combination therapy for radical cure of vivax malaria in Indonesian soldiers in East Java (GSK UK, Medicines for Malaria Venture, Geneva, and the Bill & Melinda Gates Foundation);
  • a randomized, double-blind, placebo-controlled trial of live Plasmodium falciparum sporozoite vaccines for prevention of acute P. falciparum and acute and latent Plasmodium vivax malaria in Indonesian soldiers (US Congressionally Directed Medical Research Program & Sanaria Inc., USA).

FMUI faculty members serve as the Principal Investigators of each of these endeavours, along FMUI, EIMB (including EOCRU), Oxford University Clinical Research Unit Viet Nam (OUCRU), and Armed Forces of Indonesia co-investigators and technical staff.

The IOCRL facility, managed by Dr Raph Hamers of Oxford University (Centre for Tropical Medicine & Global Health), serves as the administrative, regulatory, and technical hub for these complex and ambitious trials. This remarkably productive engagement of Oxford University with EIMB and FMUI approaches its tenth year with a sense of deep gratitude to these hosts for their warm Indonesian hospitality, collegiality, friendship, and professionalism.

Similar stories

Picturing Health: The Burden of Leprosy in Eastern Indonesia

The Eijkman Oxford Clinical Research Unit in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualize the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease

Research Culture at OUCRU

What do we mean by 'Research Culture' and how has fostering a multinational, collaborative culture helped us deliver world-class research? Let's explore the research culture at OUCRU.

Policy and Public Engagement at OUCRU

Why does OUCRU place an important focus on engaging with its important partners, policy makers, the press, the community, and young people? Explore our work in policy & public engagement.

World TB Day 2022: Invest to End TB. Save Lives

Each year on 24 March, World TB Day is commemorated to raise awareness of this devastating and deadly disease. The theme for this year’s World TB Day is “Invest to End TB. Save Lives”, conveying the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

OUCRU Research Themes and Future

In this video, explore OUCRU's research areas and what questions we are aiming to answer in the next 5 years.